SHOULD WOMEN ATTENDING FRACTURE CLINICS BE COUNSELED ABOUT OSTEOPOROSIS

被引:6
作者
GUNDLE, R
SIMPSON, AHRW
机构
[1] The Accident Service, John Radcliffe Hospital, Oxford
来源
INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED | 1993年 / 24卷 / 07期
关键词
D O I
10.1016/0020-1383(93)90144-U
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Osteoporotic fractures cause much morbidity and mortality and are a great burden on health care resources. It is well established that hormone replacement therapy (HRT) reduces the risk of osteoporotic fracture, it is also known to be worth initiating therapy even when one osteoporotic fracture has occurred in order to reduce the incidence of further fractures In this study, detailed questionnaires assessing risk factors for osteoporosis were given to all women aged 25-60 years attending a daily fracture clinic over a 10-week period, and their radiographs were studied for signs of early trabecular bone loss, in order to determine whether at-risk patients could be identified easily. The findings were that 50 per cent of the premenopausal women had lifestyle-related risk factors about which they could be counselled. Using current guidelines, 90 per cent of the peri- and post-menopausal group should be considered for HRT Overall, only 7 per cent of patients who should be on HRT were receiving it. It was concluded that most of those at risk ran be identified very simply in the fracture clinic. This aspect of fracture management is currently being neglected.
引用
收藏
页码:441 / 442
页数:2
相关论文
共 8 条
[1]  
Belchetz, Hormone replacement treatment, Br. Med. J., 298, (1989)
[2]  
Ettinger, Genant, Cann, Long-term estrogen replacement therapy prevents bone loss and fractures, Ann. Int. Med., 102, (1985)
[3]  
Osteoporosis: Prevention and Treatment, Drug and Therapeutics Bulletin, 27, (1989)
[4]  
Paganini-Hill, Ross, Gerkins, Et al., Menopausal estrogen therapy and hip fractures, Ann. Int. Med., 95, (1981)
[5]  
Riggs, Seeman, Hodgson, Et al., Effect of the fluoride/calcium regimen on vertebral fracture occurrence in postmenopausal osteoporosis: comparison with conventional therapy, N. Engl. J. Med., 306, (1982)
[6]  
Stampfer, Colditz, Willet, Et al., Postmenopausal oestrogen therapy and cardiovascular disease, N. Engl. J. Med., 325, (1991)
[7]  
Wallace, The scale and financial implications of osteoporosis, Int. Med., (1987)
[8]  
Weiss, Ure, Ballard, Et al., Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen, N. Engl. J. Med., 303, (1980)